Commission Implementing Regulation (EU) 2020/869 of 24 June 2020 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances beflubutamid, benalaxyl, benthiavalicarb, bifenazate, boscalid, bromoxynil, captan, cyazofamid, dimethomorph, ethephon, etoxazole, famoxadone, fenamiphos, flumioxazine, fluoxastrobin, folpet, formetanate, metribuzin, milbemectin, Paecilomyces lilacinus strain 251, phenmedipham, phosmet, pirimiphos-methyl, propamocarb, prothioconazole and S-metolachlor (Text with EEA relevance)

• CELEX: Implementing Regulation (EU) 2020/869
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 35, Famoxadone, the date is replaced by ‘30 June 2021’;

(2)

in the sixth column, expiration of approval, of row 39, Flumioxazine, the date is replaced by ‘30 June 2021’;

(3)

in the sixth column, expiration of approval, of row 46, Cyazofamid, the date is replaced by ‘31 July 2021’;

(4)

in the sixth column, expiration of approval, of row 84, Benalaxyl, the date is replaced by ‘31 July 2021’;

(5)

in the sixth column, expiration of approval, of row 85, Bromoxynil, the date is replaced by ‘31 July 2021’;

(6)

in the sixth column, expiration of approval, of row 88, Phenmedipham, the date is replaced by ‘31 July 2021’;

(7)

in the sixth column, expiration of approval, of row 97, S-metolachlor, the date is replaced by ‘31 July 2021’;

(8)

in the sixth column, expiration of approval, of row 99, Etoxazole, the date is replaced by ‘31 July 2021’;

(9)

in the sixth column, expiration of approval, of row 109, Bifenazate, the date is replaced by ‘31 July 2021’;

(10)

in the sixth column, expiration of approval, of row 110, Milbemectin, the date is replaced by ‘31 July 2021’;

(11)

in the sixth column, expiration of approval, of row 141, Fenamiphos, the date is replaced by ‘31 July 2021’;

(12)

in the sixth column, expiration of approval, of row 142, Ethephon, the date is replaced by ‘31 July 2021’;

(13)

in the sixth column, expiration of approval, of row 145, Captan, the date is replaced by ‘31 July 2021’;

(14)

in the sixth column, expiration of approval, of row 146, Folpet, the date is replaced by ‘31 July 2021’;

(15)

in the sixth column, expiration of approval, of row 147, Formetanate, the date is replaced by ‘31 July 2021’;

(16)

in the sixth column, expiration of approval, of row 150, Dimethomorph, the date is replaced by ‘31 July 2021’;

(17)

in the sixth column, expiration of approval, of row 152, Metribuzin, the date is replaced by ‘31 July 2021’;

(18)

in the sixth column, expiration of approval, of row 153, Phosmet, the date is replaced by ‘31 July 2021’;

(19)

in the sixth column, expiration of approval, of row 154, Propamocarb, the date is replaced by ‘31 July 2021’;

(20)

in the sixth column, expiration of approval, of row 156, Pirimiphos-methyl, the date is replaced by ‘31 July 2021’;

(21)

in the sixth column, expiration of approval, of row 158, Beflubutamid, the date is replaced by ‘31 July 2021’;

(22)

in the sixth column, expiration of approval, of row 163, Benthiavalicarb, the date is replaced by ‘31 July 2021’;

(23)

in the sixth column, expiration of approval, of row 164, Boscalid, the date is replaced by ‘31 July 2021’;

(24)

in the sixth column, expiration of approval, of row 166, Fluoxastrobin, the date is replaced by ‘31 July 2021’;

(25)

in the sixth column, expiration of approval, of row 167, Paecilomyces lilacinus strain 251, the date is replaced by ‘31 July 2021’;

(26)

in the sixth column, expiration of approval, of row 168, Prothioconazole, the date is replaced by ‘31 July 2021’.